Recorded Pharmacist Educational Series: Gene & Cell Therapy Educational Series: Part 1 – Identifying the Gene & Cell Therapy Education Gap in Health-System Pharmacy Practice
ACPE Activity Number:0204-0000-25-026-H05-P Release Date: February 26, 2025 Expiration Date: February 26, 2027 Activity Type: Knowledge-based CE Credits: 0.5 contact hours, no partial credit Activity Fee: Member – Free / Non-Member – Not Available
Activity Overview
Gene and cell therapies are quickly integrating into pharmacy practice and present unique challenges not encountered with traditional medications in the clinical pharmacy setting. Health-system pharmacies must take an active role in onboarding these therapies including evaluating biosafety precautions along the medication use pathway,assisting with the development of infrastructure to administer and monitor these therapies, and identifying the practical and financial implications of these therapies within the health-system.
This activity will describe a gap analysis of translational gene therapy processes between the research and clinical setting, while overviewing the applicable guidance documents for the development of comprehensive safe handling procedures for gene and cell therapies in clinical pharmacy practice.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity series was planned to meet the educational needs of health-system pharmacists and pharmacy leaders overseeing novel gene and cell therapies in the clinical pharmacy environment.
After participating in this CPE activity, participants should be able to:
Identify potential translational gaps for the use of emerging gene and cell therapies in a health-system pharmacy.
Recall regulatory and guidance documents that drive current best practice and safe handling recommendations for gene and cell therapies across the clinical and research environments.
Describe risk mitigation strategies for the development of standard operating procedures of gene and cell therapies.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
